C. Léonce

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

J. Blay, D. Planchard, J. Mazières, 2020, Clinical Cancer Research.

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

D. Planchard, P. Saintigny, L. Lacroix, 2020, PloS one.

Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.

S. Boyault, S. Lantuejoul, C. Caux, 2022, European journal of cancer.

Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer

P. Saintigny, S. Ortiz-Cuaran, C. Leonce, 2021, Molecular Cancer Research.

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.

E. Felip, D. Planchard, V. Ludovini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.